Thyroid drug recalled nationwide over superpotency risk

Vitruvias Therapeutics is voluntarily recalling one lot of Thyroid Tablets, USP 30 milligrams after testing found the product could be more potent than intended. The consumer-level recall covers Lot 504950, which was distributed nationwide to Vitruvias Therapeutics’ direct accounts from Jan. 31 through Sept. 30, 2025, according to an Aug. 21 company announcement published by […] The post Thyroid drug recalled nationwide over superpotency risk appeared first on Becker's Hospital...